Read more

September 11, 2023
1 min read
Save

Top in cardiology: Obesity-related CV deaths triple; benefits of bystander defibrillation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The rate of obesity-related cardiovascular deaths tripled from 1999 to 2020 — a rise that has taken the greatest toll on underrepresented groups, according to a study.

It was the top story in cardiology last week.

Heart 2_Shutterstock
Cardiovascular deaths related to obesity have tripled over the past 2 decades, according to a study. Image: Adobe Stock

In another top story, researchers studying out-of-hospital cardiac arrests found that bystander use of an automated external defibrillator improved survival at 30 days, even with a quick EMS response.

Read these and more top stories in cardiology below:

Obesity-related heart disease deaths triple since 1999, with highest impact on Black women

Cardiovascular deaths related to obesity increased by 200% across all race groups from 1999 to 2020, a statistic researchers said reflects the health consequences of the rising burden of obesity in the United States. Read more.

Bystander defibrillation after cardiac arrest improves survival with quick EMS response

Adults are more likely to survive an out-of-hospital cardiac arrest if they receive bystander defibrillation, even when an ambulance arrives within as little as 2 minutes, researchers reported. Read more.

The best defense against sudden cardiac death: Emergency action plans, CPR and AEDs

When Damar Hamlin of the Buffalo Bills went into sudden cardiac arrest Jan. 2, 2023, during a “Monday Night Football” game, we were all reminded of the importance of a plan. Read more.

Topline phase 2 data show potent, dose-dependent BP reduction with zilebesiran

An investigational RNA interference agent targeting angiotensin demonstrated a dose-dependent, clinically significant reduction in 24-hour mean systolic BP in adults with hypertension in a phase 2 trial, according to a press release. Read more.

‘It is rarely too late’ to initiate eplerenone for HFrEF

Initiation of the nonsteroidal mineralocorticoid receptor antagonist eplerenone shows benefit in patients with HF with reduced ejection fraction, regardless of their disease duration, 1 year or more than 5 years, a speaker reported. Read more.